Literature DB >> 18057051

Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis.

E Daviskas1, S D Anderson, S Eberl, I H Young.   

Abstract

Bronchiectasis is characterised by hypersecretion and impaired clearance of mucus. A 400-mg dose of inhaled mannitol improves mucus clearance however, the effect of other doses is unknown. A total of 14 patients, aged 63.3+/-5.7 yrs, were studied on five visits. Mucus clearance at baseline and with mannitol (160, 320 and 480 mg) was measured using technetium-99m-sulphur colloid and imaging with a gamma camera over 45 min, followed by a further 30 min involving 100 voluntary coughs. A control study assessed the effect of cough provoked by mannitol during the intervention. Whole right lung clearance over 45 min was 4.7+/-1.2 and 10.6+/-2.6% on baseline and control days, respectively, and increased to 16.7+/-4.2, 22.8+/-4.2 and 31+/-4.7% with 160, 320 and 480 mg mannitol, respectively. Clearance over 45 min with 480 mg mannitol was greater than clearance with 320 and 160 mg. Total clearance over 75 min, after mannitol administration and voluntary coughs, was 36.1+/-5.5, 40.9+/-5.6 and 46.0+/-5.2% with 160, 320 and 480 mg mannitol, respectively, all significantly different from baseline (24.1+/-6.0%) and control (13.1+/-3.0%). Total clearance over 75 min with 480 mg mannitol was greater compared with 160 mg. In conclusion, mucus clearance increases with increasing doses of mannitol and can be further increased by cough in patients with bronchiectasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18057051     DOI: 10.1183/09031936.00119707

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

Review 1.  Pharmacological treatment options for bronchiectasis: focus on antimicrobial and anti-inflammatory agents.

Authors:  Jonathan Ilowite; Peter Spiegler; Heather Kessler
Journal:  Drugs       Date:  2009       Impact factor: 9.546

2.  Overnight delivery of hypertonic saline by nasal cannula aerosol for cystic fibrosis.

Authors:  Timothy E Corcoran; Joseph E Godovchik; Karl H Donn; David R Busick; Jennifer Goralski; Landon W Locke; Matthew R Markovetz; Michael M Myerburg; Ashok Muthukrishnan; Lawrence Weber; Ryan T Lacy; Joseph M Pilewski
Journal:  Pediatr Pulmonol       Date:  2017-07-24

3.  Therapeutic aerosol bioengineering of targeted, inhalable microparticle formulations to treat Mycobacterium tuberculosis (MTb).

Authors:  C Lawlor; M P O'Sullivan; B Rice; P Dillon; P J Gallagher; S O'Leary; S Shoyele; J Keane; S-A Cryan
Journal:  J Mater Sci Mater Med       Date:  2011-12-20       Impact factor: 3.896

Review 4.  Airway clearance techniques for bronchiectasis.

Authors:  Annemarie L Lee; Angela T Burge; Anne E Holland
Journal:  Cochrane Database Syst Rev       Date:  2015-11-23

Review 5.  New pulmonary therapies directed at targets other than CFTR.

Authors:  Scott H Donaldson; Luis Galietta
Journal:  Cold Spring Harb Perspect Med       Date:  2013-06-01       Impact factor: 6.915

Review 6.  Pulmonary delivery of therapeutic siRNA.

Authors:  Jenny Ka-Wing Lam; Wanling Liang; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2011-02-26       Impact factor: 15.470

7.  Rapid changes in mucociliary transport in the tracheal epithelium caused by unconditioned room air or nebulized hypertonic saline and mannitol are not determined by frequency of beating cilia.

Authors:  Susyn Joan Kelly; Paul Martinsen; Stanislav Tatkov
Journal:  Intensive Care Med Exp       Date:  2021-03-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.